🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Stacey L. Berg

University of Twente

ORCID: 0000-0003-2832-9994
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile
0.257Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps10071
Top 59%
0.257DataRank
Top 59%3 citations

Katherine A. Janeway, Theodore W. Laetsch, Meredith S. Irwin, Elizabeth Alva, Christine A. Pratilas +14 more

Papers

Driven by 16 papers — median percentile 41. Top paper: “Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial”.

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30023-1
N/A
5.0DataRank · unranked
337 citations

Elizabeth Fox, Melinda S. Merchant, Joel M. Reid, Rachel A. Kudgus, Xiaowei Liu +6 more

Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute–Children's Oncology Group Pediatric MATCH Trial

Journal of Clinical Oncology(2022)10.1200/jco.21.02838
N/A
0.722DataRank · unranked
122 citations

Katherine A. Janeway, David R. Patton, Cynthia L. Winter, Brent Coffey, P. Mickey Williams +16 more

Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad085
N/A
0.685DataRank · unranked
95 citations

Joanna S. Yi, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +17 more

Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3009
N/A
0.518DataRank · unranked
16 citations

Amit J. Sabnis, Paul M. Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.10009
N/A
0.464DataRank · unranked
21 citations

Joanna S. Yi, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)

European Journal of Cancer(2024)10.1016/j.ejca.2024.114241
N/A
0.416DataRank · unranked
15 citations

Joel M. Reid, Charles G. Minard, Sarah E. Woodfield, Kristina Z. Denic, Emasenyie Isikwei +7 more

Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G

The Oncologist(2024)10.1093/oncolo/oyae119
N/A
0.363DataRank · unranked
7 citations

AeRang Kim, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +17 more

Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps10071
Top 59%
0.257DataRank
Top 59%3 citations

Katherine A. Janeway, Theodore W. Laetsch, Meredith S. Irwin, Elizabeth Alva, Christine A. Pratilas +14 more

Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG pediatric MATCH trial Arm I (APEC1621I).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.10006
N/A
0.241DataRank · unranked
4 citations

Rajen Mody, Joel M. Reid, Jin Piao, Lauren Saguilig, Todd A. Alonzo +14 more

Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10019
N/A
0.208DataRank · unranked
3 citations

Joel M. Reid, Charles G. Minard, Emasenyie Isikwei, Xiaowei Liu, Stacey L. Berg +4 more

Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10007
N/A
0.208DataRank · unranked
3 citations

Katherine A. Janeway, David R. Patton, Jennifer Lee, Brent Coffey, P. Mickey Williams +16 more

Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10008
N/A
0.165DataRank · unranked
2 citations

Olive S. Eckstein, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

Data from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

(2023)10.1158/1078-0432.c.6532749
N/A
0DataRank · unranked
0 citations

Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard +5 more

Data from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

(2023)10.1158/1078-0432.c.6532749.v1
N/A
0DataRank · unranked
0 citations

Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard +5 more

A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2164
N/A
0DataRank · unranked
72 citations

Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard +5 more

Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.10007
N/A
0DataRank · unranked
20 citations

Alexander J. Chou, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more